VIVEK SUBBIAH to Doxorubicin
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Doxorubicin.
Connection Strength
0.441
-
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study. Invest New Drugs. 2023 10; 41(5):677-687.
Score: 0.139
-
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020 05; 21(5):645-654.
Score: 0.110
-
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
Score: 0.089
-
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. J Clin Oncol. 2010 Aug 20; 28(24):e415.
Score: 0.056
-
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2008 Feb 14; 358(7):743; author reply 743.
Score: 0.047